InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,436.44
(
-0.50%
)
US TECH 100
18,569.20
(
1.46%
)
Dow Jones
40,743.33
(
0.50%
)
Brent Oil
80.12
(
1.97%
)
Bitcoin
65,964.17
(
-0.31%
)
Post# of 252749
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

efar

Send PM Follow Ignore
Followers 0
Posts 60
Boards Moderated 0
Alias Born 01/06/2010

efar

Re: drbio45 post# 116872

Wednesday, 03/23/2011 3:17:02 PM

Wednesday, March 23, 2011 3:17:02 PM

Post# of 252749
Not aware of the situation with Pluristem, that does sound pretty slimy, but it looks like he initiated coverage of PSTI last year when the stock was at 1.20 and today it is more than double that at 2.50.

Also, in the Best on the Street survey released by the WSJ last year Vaino was the #1 ranked pharmaceutical analyst and The Financial Times ranked him #2 for biotech. As analysts go, I still think he is one of the more accurate...

As far as financing, I agree CYTK will need financing at some point. Right now it looks like they have enough cash to last ~4 quarters so a raise is likely in the next 9 months IMO.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up